Systematic Review of Economic Evaluations of Cycling Versus Swapping Medications in Patients With Rheumatoid Arthritis After Failure to Respond to Tumor Necrosis Factor Inhibitors

Arthritis Care & Research
Aliza R Karpes MatusevichMaria A Lopez-Olivo

Abstract

To systematically review the modeling approaches and quality of economic analyses comparing cycling tumor necrosis factor inhibitors (TNFi) to swapping to a therapy with a different mode of action in patients with rheumatoid arthritis whose initial TNFi failed. We searched electronic databases, gray literature, and references of included publications until July 2017. Two reviewers independently screened citations. Reporting quality was assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Data regarding modeling methodology were extracted. We included 7 articles comprising 19 comparisons. Three studies scored ≥16 of 24 on the CHEERS checklist. Most models used a lifetime horizon, took a payer perspective, employed a 6-month cycle length, and measured treatment efficacy in terms of the American College of Rheumatology improvement criteria. We noted possible sources of bias in terms of transparency and study sponsorship. In the cost-utility comparisons, the median incremental cost-effectiveness ratio was US $70,332 per quality-adjusted life-year for swapping versus cycling strategies. Rituximab was more effective and less expensive than TNFi in 7 of 11 comparisons. Abatacept (intraveno...Continue Reading

References

Jan 1, 1991·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M Goddard, M Drummond
Sep 15, 2005·Medical Decision Making : an International Journal of the Society for Medical Decision Making·M F DrummondJ B Wong
Feb 24, 2006·BMJ : British Medical Journal·Chaim M BellPeter J Neumann
Apr 1, 2009·International Journal of Technology Assessment in Health Care·Peter LindgrenGisela Kobelt
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Dec 8, 2009·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Sonja MerkesdalAndrea Rubbert-Roth
Jun 30, 2010·International Journal of Technology Assessment in Health Care·Livio GarattiniGianluigi Casadei
Aug 17, 2011·The Journal of Rheumatology·Stephan McBrideJoseph A Johnston
Sep 25, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Uwe SiebertUNKNOWN ISPOR-SMDM Modeling Good Research Practices Task Force
Jan 5, 2013·Scandinavian Journal of Rheumatology·K Chatzidionysiou, R F van Vollenhoven
Jan 10, 2013·Journal of Medical Economics·Sean D SullivanSarah Ringold
Mar 30, 2013·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Don HusereauUNKNOWN CHEERS Task Force
May 24, 2014·PharmacoEconomics·Alex DiamantopoulosF Dejonckheere
Aug 28, 2014·The New England Journal of Medicine·Peter J NeumannMilton C Weinstein
Sep 4, 2014·Current Rheumatology Reports·Jonathan ToshRon Akehurst
Apr 18, 2015·Bulletin of the World Health Organization·Elliot MarseilleSydney Rosen
May 30, 2017·Annals of Internal Medicine·Nick BansbackUNKNOWN CSP 551 RACAT Investigators

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.